Indivior Pharmaceuticals, Inc. (INDV) is listed on NASDAQ in Pharmaceutical Stocks. It is $34.86, -1.26%, with a $4.1B market cap. RSI is 29.9, oversold. The latest reported quarter beat estimates. Insiders were net sellers across the listed trades.
Technical Analysis
RSI (14) 29.9 Oversold
Market Cap $4.1B
Volume 809.9K
Fundamentals — 10-Q Q2 2026
Revenue $660.0M
Net Income $211.0M
EPS $1.67
Gross Margin 86.4%
Operating Margin 45.0%
Net Margin 32.0%
Debt / Equity -2.3x
P/E Ratio 20.9x
Earnings
Recent Insider Trades
| Name | Title | Type | Shares | Price | Value | Date |
|---|---|---|---|---|---|---|
| Anderson Woodrow D | Chief Accounting Officer | Buy | 1,500 | $35.69 | $53,535 | 2026 Aug 27 |
| Anderson Woodrow D | Chief Accounting Officer | Buy | 1,500 | $36.28 | $54,420 | 2026 Aug 5 |
| Heidbreder Christian | Chief Scientific Officer | Sell | 18,586 | $41.14 | $764,628 | 2026 Jul 10 |
| Heidbreder Christian | Chief Scientific Officer | Sell | 18,586 | $38.06 | $707,383 | 2026 Jun 11 |
| Preblick Ryan | Chief Financial Officer | Sell | 36,000 | $37.70 | $1.4M | 2026 Jun 8 |
| Ryan Barbara | Director | Buy | 8 | $31.09 | $249 | 2026 Mar 13 |
| Ryan Barbara | Director | Buy | 31 | $32.56 | $1,009 | 2026 Mar 9 |
| Kingsley Stuart A | Director | Buy | 940 | $31.86 | $29,953 | 2026 Mar 6 |
Other Pharmaceutical Stocks
| Ticker | Price | RSI | Mkt Cap |
|---|---|---|---|
| | $1,173.34 | 46.3 | $1.1T |
| | $268.01 | 58.6 | $645.9B |
| | $148.31 | 64.1 | $365.9B |
| | $97.41 | 36.9 | $6.3B |
Take INDV further
- Browse Pharmaceutical Stocks for the rest of the group, with what the businesses in it have in common and where they differ.
- Put INDV in a portfolio and see what it does to total return, drawdown, and how the rest of your holdings move with it. Compares against the S&P 500 over the same days, free and without an account.
- Screen for others like it by RSI, valuation, market cap, and insider activity.
- Check the earnings calendar for when Indivior Pharmaceuticals, Inc. next reports.
Set alerts on INDV
Get notified when Indivior Pharmaceuticals, Inc. hits your price targets or technical conditions are met.
Get Started Free